Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.

Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke. The study will be a dose escalation using up to 4 cohorts each at a single dose level, of intracerebral administration of NR1 cells. Secondary objectives are to evaluate clinical and radiologic responses as well as utility of efficacy measurement tools.

Inclusion Criteria:

• Age 18 - 75 years
• History of ischemic subcortical stroke in the middle cerebral artery and/or lenticulostriate artery 6 to 60 months from time of stroke
• Ability of subject to understand and provide written Informed Consent
• Willing to take tacrolimus (Prograf) 2 days before and for 2 months after transplant

Exclusion Criteria:

• Stroke lesion less than 1 cubic centimeter or greater than 100 cubic centimeters measured by MRI
• Index stroke is lacunar infarct less than 1 year old
• History or presence of any major neurological disease
• History of active cancer other than basal or squamous cell skin cancers
• History of seizures
• Pregnant or breast-feeding